Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial
Year: 2008
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Anders Osterborg, Thomas J. Kipps, Jiri Mayer, Stephan Stilgenbauer, Catherine D Williams, Andrzej Hellmen, Tadeusz Robak, Richard R Furman, Peter Hillmen, Marek Trneny, Martin J.S. Dyer, Swaminathan Padmanabhan, Tomas Kozak, Geoffrey Chan, Randy L Davis, Nedjad Losic, Charlotte A. Russell, Magdalena Piotrowska, Joris Wilms, William G. Wierda
Institutions: Karolinska University Hospital, University of California San Diego, Moores Cancer Center, University Hospital Brno, Universität Ulm, Nottingham University Hospitals NHS Trust, Gdańsk Medical University, Medical University of Lodz, Weill Cornell Medicine, St James's University Hospital, Charles University, University of Leicester, The University of Texas at San Antonio Health Science Center, University Hospital Kralovske Vinohrady, GlaxoSmithKline (United States), Genmab (Denmark), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2981310191